Non-opioid Pain Averitas Pharma offers FDA-approved non-opioid topical solutions for postherpetic neuralgia and diabetic neuropathic foot pain, presenting a growth avenue for clinicians seeking pain management alternatives with lower dependency risk.

Strategic Partnerships Recent and ongoing collaborations with research groups and patient advocacy organizations indicate a receptive ecosystem for co-promotional activities, post-market studies, and educational campaigns that can be leveraged to expand market reach.

US Market Footprint The US subsidiary emerged through a strategic acquisition, suggesting established commercial operations and potential to scale with additional support from Grünenthal’s global network to accelerate access in regional networks.

Clinical Evidence Active engagement in post-market observational studies and clinical partnerships provides opportunities to upsell expanded data-driven programs, payer negotiations, and reimbursement discussions to healthcare providers.

Awareness Campaigns Past initiatives like Name That Pain and Speak For Your Feet indicate a proven blueprint for patient and HCP education; these campaigns can be repurposed or expanded to generate demand and identify unmet needs in neuropathic pain management.